<?xml version="1.0" encoding="UTF-8"?>
<p>A new framework for risk-adapted approaches to clinical trials may be needed until a vaccine, or efficacious treatment is available [
 <xref rid="REF1" ref-type="bibr">1</xref>,
 <xref rid="REF4" ref-type="bibr">4</xref>]. Trial teams are exploring novel ways of delivering clinical trials including recruitment approaches, clinical assessments and IMP monitoring. These novel methods have emerged from an urgent need during an unprecedented time. The longer-term adaptation and implementation of such measures show promise to promote trial inclusivity for a heterogeneous population of older adults with and without chronic conditions which are both under-represented in clinical research and potentially at most significant risk of acquiring COVID-19 infection. 
</p>
